Literature DB >> 33472911

Morning for Irofulven, What Could be fiNER?

Haoyang Jiang1, Roger A Greenberg2.   

Abstract

Cancers with DNA repair dysfunction are vulnerable to DNA-damaging agents that invoke a requirement for the disabled repair mechanism. Genome sequencing, coupled with a detailed understanding of mechanisms of DNA repair, has accelerated the discovery of pathway-selective agents that target DNA repair deficiencies in a tumor tissue agnostic manner.See related articles by Topka et al., p. 1997 and Börcsök et al., p. 2011. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33472911      PMCID： PMC8026716          DOI： 10.1158/1078-0432.CCR-20-4708

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  9 in total

Review 1.  Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Authors:  Alan Ashworth; Christopher J Lord
Journal:  Nat Rev Clin Oncol       Date:  2018-09       Impact factor: 66.675

Review 2.  Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.

Authors:  Andrew V Anzalone; Luke W Koblan; David R Liu
Journal:  Nat Biotechnol       Date:  2020-06-22       Impact factor: 54.908

Review 3.  Integrating genetic approaches into the discovery of anticancer drugs.

Authors:  L H Hartwell; P Szankasi; C J Roberts; A W Murray; S H Friend
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

4.  A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Authors:  Michael V Seiden; Alan N Gordon; Diane C Bodurka; Ursula A Matulonis; Richard T Penson; Eddie Reed; Dave S Alberts; Garry Weems; Michael Cullen; William P McGuire
Journal:  Gynecol Oncol       Date:  2005-11-02       Impact factor: 5.482

5.  Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways.

Authors:  Nicolaas G J Jaspers; Anja Raams; Michael J Kelner; Jessica M Y Ng; Yukiko M Yamashita; Shiunichi Takeda; Trevor C McMorris; Jan H J Hoeijmakers
Journal:  DNA Repair (Amst)       Date:  2002-12-05

6.  Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer.

Authors:  Sabine Topka; Zoe Steinsnyder; Vignesh Ravichandran; Kaitlyn Tkachuk; Yelena Kemel; Chaitanya Bandlamudi; Mogens Winkel Madsen; Helena Furberg; Ouathek Ouerfelli; Charles M Rudin; Gopa Iyer; Steven M Lipkin; Semanti Mukherjee; David B Solit; Michael F Berger; Dean F Bajorin; Jonathan E Rosenberg; Barry S Taylor; Elisa de Stanchina; Joseph Vijai; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2020-11-16       Impact factor: 12.531

7.  Mutational processes molding the genomes of 21 breast cancers.

Authors:  Serena Nik-Zainal; Ludmil B Alexandrov; David C Wedge; Peter Van Loo; Christopher D Greenman; Keiran Raine; David Jones; Jonathan Hinton; John Marshall; Lucy A Stebbings; Andrew Menzies; Sancha Martin; Kenric Leung; Lina Chen; Catherine Leroy; Manasa Ramakrishna; Richard Rance; King Wai Lau; Laura J Mudie; Ignacio Varela; David J McBride; Graham R Bignell; Susanna L Cooke; Adam Shlien; John Gamble; Ian Whitmore; Mark Maddison; Patrick S Tarpey; Helen R Davies; Elli Papaemmanuil; Philip J Stephens; Stuart McLaren; Adam P Butler; Jon W Teague; Göran Jönsson; Judy E Garber; Daniel Silver; Penelope Miron; Aquila Fatima; Sandrine Boyault; Anita Langerød; Andrew Tutt; John W M Martens; Samuel A J R Aparicio; Åke Borg; Anne Vincent Salomon; Gilles Thomas; Anne-Lise Børresen-Dale; Andrea L Richardson; Michael S Neuberger; P Andrew Futreal; Peter J Campbell; Michael R Stratton
Journal:  Cell       Date:  2012-05-17       Impact factor: 41.582

8.  Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.

Authors:  Judit Börcsök; Zsofia Sztupinszki; Raie Bekele; Sizhi P Gao; Miklos Diossy; Amruta S Samant; Kasia M Dillon; Viktoria Tisza; Sándor Spisák; Orsolya Rusz; Istvan Csabai; Helle Pappot; Zoë J Frazier; David J Konieczkowski; David Liu; Naresh Vasani; James A Rodrigues; David B Solit; Jean H Hoffman-Censits; Elizabeth R Plimack; Jonathan E Rosenberg; Jean-Bernard Lazaro; Mary-Ellen Taplin; Gopa Iyer; Søren Brunak; Rita Lozsa; Eliezer M Van Allen; Dávid Szüts; Kent W Mouw; Zoltan Szallasi
Journal:  Clin Cancer Res       Date:  2020-11-18       Impact factor: 13.801

9.  Repeat expansions confer WRN dependence in microsatellite-unstable cancers.

Authors:  Niek van Wietmarschen; Sriram Sridharan; William J Nathan; Anthony Tubbs; Edmond M Chan; Elsa Callen; Wei Wu; Frida Belinky; Veenu Tripathi; Nancy Wong; Kyla Foster; Javad Noorbakhsh; Kiran Garimella; Abimael Cruz-Migoni; Joshua A Sommers; Yongqing Huang; Ashir A Borah; Jonathan T Smith; Jeremie Kalfon; Nikolas Kesten; Kasper Fugger; Robert L Walker; Egor Dolzhenko; Michael A Eberle; Bruce E Hayward; Karen Usdin; Catherine H Freudenreich; Robert M Brosh; Stephen C West; Peter J McHugh; Paul S Meltzer; Adam J Bass; André Nussenzweig
Journal:  Nature       Date:  2020-09-30       Impact factor: 69.504
  9 in total
  2 in total

1.  PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.

Authors:  Alexander von Werdt; Laura Brandt; Orlando D Schärer; Mark A Rubin
Journal:  JCO Precis Oncol       Date:  2021-10-22

2.  Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance.

Authors:  Long Li; Qiang Zhao; Jincheng Ma; Yan Jin; Baocheng Gong
Journal:  Discov Oncol       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.